Lv3
290 积分 2023-10-20 加入
Belantamab Mafodotin As Pre- and Post-Autologous Stem Cell Transplant (ASCT) Consolidation and Maintenance for Multiple Myeloma (MM) with < CR after Induction: Interim Results of the Ongoing Phase 2 BLAST Study
1个月前
已关闭
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
2个月前
已完结
Trends in the multiple myeloma treatment landscape and survival: a U.S. analysis using 2011-2019 oncology clinic electronic health record data
2个月前
已完结
Belantamab mafodotin, lenalidomide and dexamethasone (BelaRd) in newly diagnosed intermediate-fit and frail myeloma
2个月前
已关闭
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
3个月前
已完结
Outcomes of elranatamab in relapsed/refractory multiple myeloma: prognostic impact of monocyte count, MyCARe, and R2-ISS
3个月前
已完结
Antibody-Drug Conjugates, T-Cell Engager Bispecific Antibodies and Chimeric Antigen Receptor T Cells for Multiple Myeloma: What's the Current Status?
3个月前
已关闭
CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma
3个月前
已完结
Antibody-Drug Conjugates, T-Cell Engager Bispecific Antibodies and Chimeric Antigen Receptor T Cells for Multiple Myeloma: What's the Current Status?
3个月前
已关闭
Bispecific antibodies in multiple myeloma: maximizing potential through rational combination therapies
3个月前
已关闭
皖公网安备34019202002308
